• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
Conclusion  Glucagon-like peptide-1 receptor agonists significantly reduce MACE, CV and total mortality stroke, and hospitalization for HF, with a trend for reduction of MI, in patients with Type 2 DM with and without established CVD.
Source: European Heart Journal - February 20, 2020 Category: Cardiology Source Type: research

Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial
ConclusionRoutine ingestion by hypertensive patients of ≥1 prescribed BP-lowering medications at bedtime, as opposed to upon waking, results in improved ABP control (significantly enhanced decrease in asleep BP and increased sleep-time relative BP decline, i.e. BP dipping) and, most importantly, markedly diminished occurrence of major CVD events.Trial registrationClinicalTrials.gov, number NCT00741585. 
Source: European Heart Journal - October 22, 2019 Category: Cardiology Source Type: research

Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes
Conclusion  Plasma TML levels, alone and together with TMAO, are associated with both near- and long-term CV events in patients with chest pain and ACS.
Source: European Heart Journal - April 23, 2019 Category: Cardiology Source Type: research

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500  000 patients with Type 2 diabetes mellitus
ConclusionCardiovascular disease-free life expectancy and effects of lifelong prevention in terms of CVD-free life-years gained can be estimated for people with T2DM using readily available clinical characteristics. Predictions of individual-level treatment effects facilitate translation of trial results to individual patients.
Source: European Heart Journal - January 9, 2019 Category: Cardiology Source Type: research

Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)
ConclusionsCoronary artery calcium is associated strongly and in a graded fashion with 10-year risk of incident ASCVD as it is for CHD, independent of standard risk factors, and similarly by age, gender, and ethnicity. While 10-year event rates in those with CAC  = 0 were almost exclusively below 5%, those with CAC ≥ 100 were consistently above 7.5%, making these potentially valuable cutpoints for the consideration of preventive therapies. Coronary artery calcium strongly predicts risk with the same magnitude of effect in all races, age groups, an d both sexes, which makes it among the most useful markers for predicting ASCVD risk.
Source: European Heart Journal - April 23, 2018 Category: Cardiology Source Type: research

Clinical impact of direct stenting and interaction with thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Thrombectomy Trialists Collaboration
ConclusionDirect stenting rates were higher in patients randomized to thrombus aspiration. Clinical outcomes and myocardial reperfusion measures did not differ significantly between DS and conventional stenting and there was no interaction with thrombus aspiration.
Source: European Heart Journal - April 21, 2018 Category: Cardiology Source Type: research

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
ConclusionCompared with TAT, DAT shows a reduction in TIMI major or minor bleeding by 47% with comparable outcomes of MACE. Our findings support the concept that DAT may be a better option than TAT in many patients with AF following PCI.
Source: European Heart Journal - April 13, 2018 Category: Cardiology Source Type: research

Predicting the development of in-hospital cardiogenic shock in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: the ORBI risk score
ConclusionThe ORBI risk score provides a readily useable and efficient tool to identify patients at high-risk of developing CS during hospitalization following STEMI, which may aid in further risk-stratification and thus potentially facilitate pre-emptive clinical decision making.
Source: European Heart Journal - March 15, 2018 Category: Cardiology Source Type: research

Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk
ConclusionsIn patients with diabetes and elevated CV risk, even after extensive adjustment for underlying disease burden, there was a persistent association for low DBP with subclinical myocardial injury and risk of MI.
Source: European Heart Journal - January 31, 2018 Category: Cardiology Source Type: research

Weight gain after smoking cessation does not modify its protective effect on myocardial infarction and stroke: evidence from a cohort study of men
ConclusionPost-cessation BMI change did not significantly modify the protective association of smoking cessation with MI and stroke.
Source: European Heart Journal - January 6, 2018 Category: Cardiology Source Type: research

External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry
ConclusionCOMPASS-Eligible patients represent a substantial fraction of stable CAD/PAD patients encountered in routine clinical practice in the large international REACH registry suggesting good external applicability. COMPASS-Eligible patients experienced a higher rate of the primary outcome compared with COMPASS participants in the aspirin alone treatment arm.
Source: European Heart Journal - November 23, 2017 Category: Cardiology Source Type: research

Cholesterol variability: a marker for increased risk or a risk factor?
This editorial refers to ‘Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study’†, by M.K. Kimet al., on page3560.
Source: European Heart Journal - November 13, 2017 Category: Cardiology Source Type: research

A meta-analysis of continuous positive airway pressure therapy in prevention of cardiovascular events in patients with obstructive sleep apnoea
ConclusionCPAP therapy might reduce MACE and stroke among subjects with CPAP time exceeding 4  h/night. Additional randomized trials mandating adequate CPAP time adherence are required to confirm this impression.
Source: European Heart Journal - October 24, 2017 Category: Cardiology Source Type: research

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
ConclusionReduction of MVE is proportional to the magnitude of LDL-C lowering across a broad spectrum of on-treatment levels in secondary prevention. Statin intensification and add-on treatment with PCSK9 inhibitors or ezetimibe are associated with significant reduction of cardiovascular morbidity in this very high-risk population.
Source: European Heart Journal - October 23, 2017 Category: Cardiology Source Type: research

Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study
ConclusionHigh variability in lipid levels is associated with adverse health-related outcomes. These findings suggest that lipid variability is an important risk factor in the general population.
Source: European Heart Journal - October 21, 2017 Category: Cardiology Source Type: research

Pages: 1  2  3  4  5  6  7  8